Objective: To evaluate the efficacy of Astragalus Injection on asthma. Methods: CNKI, VIP, Wan Fang Database, Medline, Embase, Web of Science and Cochrane Library were searched for published researches up to November, 2020. Randomized controlled trials that focused on Astragalus Injection for asthma were included. We managed the data analysis with RevMan 5.3 software. Results: A total of 17 RCTs with 1648 patients were involved in the meta-analysis which indicated that Astragalus Injection could improve clinical efficacy[OR = 4.72, 95%CI(3.08,7.24), P < 0.00001] and improve FEV1[MD = 0.48, 95%CI(0.32,0.64), P < 0.00001], while reduce IL-4[MD = -6.29, 95%CI(-8.91,-3.66), P < 0.00001], IL-6[MD = -18.46, 95%CI(-23.17,-13.75), P < 0.00001] and IL-17[MD = -3.14, 95%CI(-5.51,-0.76), P < 0.00001] and decrease adverse events[OR = 0.18, 95%CI(0.08,0.43), P = 0.0001]. Conclusion: Astragalus Injection is more effective and of safety, but more RCTs are needed. [ABSTRACT FROM AUTHOR]